Trinity Biotech Statistics
Total Valuation
Trinity Biotech has a market cap or net worth of $14.28 million. The enterprise value is $147.42 million.
Important Dates
The next estimated earnings date is Tuesday, June 30, 2026, before market open.
| Earnings Date | Jun 30, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Trinity Biotech has 20.25 million shares outstanding. The number of shares has increased by 3.43% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 20.25M |
| Shares Change (YoY) | +3.43% |
| Shares Change (QoQ) | +0.30% |
| Owned by Insiders (%) | 2.79% |
| Owned by Institutions (%) | 4.77% |
| Float | 16.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.33 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.37 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.25
| Current Ratio | 0.25 |
| Quick Ratio | 0.11 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -0.75 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -5.72% |
| Return on Invested Capital (ROIC) | -15.65% |
| Return on Capital Employed (ROCE) | 26.48% |
| Weighted Average Cost of Capital (WACC) | 7.53% |
| Revenue Per Employee | $152,561 |
| Profits Per Employee | -$130,230 |
| Employee Count | 287 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 1.41 |
Taxes
In the past 12 months, Trinity Biotech has paid $199,000 in taxes.
| Income Tax | 199,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6.20% in the last 52 weeks. The beta is 0.93, so Trinity Biotech's price volatility has been similar to the market average.
| Beta (5Y) | 0.93 |
| 52-Week Price Change | +6.20% |
| 50-Day Moving Average | 0.64 |
| 200-Day Moving Average | 0.88 |
| Relative Strength Index (RSI) | 60.59 |
| Average Volume (20 Days) | 123,841 |
Short Selling Information
The latest short interest is 242,867, so 1.23% of the outstanding shares have been sold short.
| Short Interest | 242,867 |
| Short Previous Month | 233,333 |
| Short % of Shares Out | 1.23% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.35 |
Income Statement
In the last 12 months, Trinity Biotech had revenue of $43.79 million and -$37.38 million in losses. Loss per share was -$2.01.
| Revenue | 43.79M |
| Gross Profit | 16.89M |
| Operating Income | -9.55M |
| Pretax Income | -37.18M |
| Net Income | -37.38M |
| EBITDA | -8.24M |
| EBIT | -9.55M |
| Loss Per Share | -$2.01 |
Full Income StatementBalance Sheet
The company has $5.14 million in cash and $137.98 million in debt, with a net cash position of -$132.85 million or -$6.56 per share.
| Cash & Cash Equivalents | 5.14M |
| Total Debt | 137.98M |
| Net Cash | -132.85M |
| Net Cash Per Share | -$6.56 |
| Equity (Book Value) | -71.98M |
| Book Value Per Share | -3.85 |
| Working Capital | -105.31M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$5.93 million and capital expenditures -$88,000, giving a free cash flow of -$6.02 million.
| Operating Cash Flow | -5.93M |
| Capital Expenditures | -88,000 |
| Depreciation & Amortization | 1.30M |
| Net Borrowing | 11.81M |
| Free Cash Flow | -6.02M |
| FCF Per Share | -$0.30 |
Full Cash Flow StatementMargins
Gross margin is 38.57%, with operating and profit margins of -21.80% and -85.36%.
| Gross Margin | 38.57% |
| Operating Margin | -21.80% |
| Pretax Margin | -84.91% |
| Profit Margin | -85.36% |
| EBITDA Margin | -18.83% |
| EBIT Margin | -21.80% |
| FCF Margin | n/a |
Dividends & Yields
Trinity Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.43% |
| Shareholder Yield | -3.43% |
| Earnings Yield | -256.48% |
| FCF Yield | -41.29% |
Dividend DetailsAnalyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 23, 2024. It was a reverse split with a ratio of 1:5.
| Last Split Date | Feb 23, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
Trinity Biotech has an Altman Z-Score of -2.58 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.58 |
| Piotroski F-Score | 3 |
